Published: 1 July 2021

Authors: Kevin L. Winthrop, Patrick A. Flume, Rachel Thomson, Kevin C. Mange, Dayton W. Yuen, Monika Ciesielska, Kozo Morimoto, Stephen J. Ruoss, Luigi R. Codecasa, Jae-Joon Yim, Theodore K. Marras, Jakko van Ingen,Richard J. Wallace, Jr., Barbara A. Brown-Elliott, Chris Coulter, and David E. Griffith*; for the INS-312 Study Group

Source: This abstract has been sourced from NZ Respiratory Research Review Issue 199


    Rationale: Patients with refractory Mycobacterium avium complex (MAC) lung disease have limited treatment options. In the CONVERT study, amikacin liposome inhalation suspension (ALIS) added to guideline-based therapy (GBT) increased culture conversion rates versus GBT alone by Month 6. Limited data are available regarding >6-month treatment in a refractory population.

    Objectives: Evaluate 12-month safety, tolerability, and efficacy of ALIS+GBT.

    Methods: Adults with refractory MAC lung disease not achieving culture conversion by CONVERT Month 6 could enroll in this open-label extension (INS-312) to receive 590 mg once-daily ALIS+GBT for 12 months. Two cohorts enrolled: the “ALIS-naive” cohort included patients randomized to GBT alone in CONVERT, and the “prior-ALIS” cohort included those randomized to ALIS+GBT in CONVERT. Safety and tolerability of ALIS over 12 months (primary endpoint) and culture conversion by Months 6 and 12 were assessed.

    Results: In the ALIS-naive cohort, 83.3% of patients (n = 75/90) experienced respiratory treatment-emergent adverse events (TEAEs), and 35.6% (n = 32) had serious TEAEs; 26.7% (n = 24) achieved culture conversion by Month 6 and 33.3% (n = 30) by Month 12. In the prior-ALIS cohort, 46.6% of patients (n = 34/73) experienced respiratory TEAEs, and 27.4% (n = 20) had serious TEAEs; 9.6% (n = 7) achieved culture conversion by Month 6 (≤14 mo ALIS exposure) and 13.7% (n = 10) by Month 12 (≤20 mo ALIS exposure). Nephrotoxicity-related TEAEs and measured hearing decline were infrequent in both cohorts.

    Conclusions: In up to 20 months of ALIS use, respiratory TEAEs were common, nephrotoxicity and hearing decline were infrequent, and culture conversion continued beyond 6 months of therapy.

    Clinical trial registered with (NCT02628600).

    Link to PDF

    Have you read

    View all